Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of Muta™Mice treated with 5,9-dimethyldibenzo[c,g]carbazole

The purpose of this work was to investigate the impact of cell proliferation on liver mutagenesis. The genotoxic hepatocarcinogen 5,9-dimethyldibenzo[c,g]carbazole (DMDBC) was administered to lacZ transgenic Muta(TM)Mice at a nonhepatotoxic dose of 10 mg/kg, which induces only a slight increase in the liver lacZ mutant frequency (RIF), To determine if cell proliferation stimuli enhanced DMDBC mutagenicity, MF was analyzed in mice first receiving DMDBC 10 mg/kg, then similar to 2 weeks later, either carbon tetrachloride (CCl4, a cytotoxic agent inducing regenerative cell proliferation) or phenobarbital (PB, a mitogenic agent inducing direct hyperplasia). In preliminary studies, the extent of cell proliferation induced by CCl4, PB and DMDBC was determined in non-transgenic CD2F1 mice by means of 5-bromadeoxyuridine labeling. The labeling index was significantly increased after CCl4 and PB, while no change was detected with DMDBC. MF was then determined in Muta(TM)Mice 28 days after initial DMDBC treatment. No increase in MF was detected in mice receiving CCl4 or PB alone. A 2- to 3-fold increase in MF was detected in mice treated with 10 mg/kg DMDBC alone. In contrast, RIF was markedly increased in mice receiving DMDBC followed by proliferative treatment (15-fold with CCl4 and 25-fold with PB), These results demonstrate that expression of DMDBC-induced mutations in mouse liver largely depends on the induction of cell proliferation (by a cytotoxic or mitogenic stimulus) and illustrate that Muta(TM)Mouse is a valuable tool to investigate the early events of liver carcinogenesis.